Acacia Pharma
Acquired by Eagle Pharmaceuticals / EURONEXT: ACPH
Develops nausea treatments for surgical and cancer patients.
F-Prime Team
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, United KingdomInitial Investment
2013
Develops nausea treatments for surgical and cancer patients.
Acacia Pharma (EURONEXT: ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Acacia developed BARHEMSYS to marketing approval and was acquired by Eagle Pharmaceuticals in 2022.